Related Experiment Video
Updated: Jun 7, 2025
08:12
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
5.4K
Biomarkers in Colorectal Cancer: Actual and Future Perspectives
Horia-Dan Lișcu1,2, Nicolae Verga2, Dimitrie-Ionuț Atasiei1
1Discipline of Oncological Radiotherapy and Medical Imaging, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
International Journal of Molecular Sciences
|November 9, 2024
Summary
This review explores colorectal cancer (CRC) biomarkers for screening, diagnosis, and prognosis. Advances in liquid biopsy, next-generation sequencing (NGS), and AI are enhancing early detection and treatment strategies.
Area of Science:
- Oncology
- Molecular Diagnostics
- Genomics
Background:
- Colorectal cancer (CRC) biomarker research is rapidly evolving.
- Current screening methods vary globally, with emerging technologies offering improved detection.
- Next-generation sequencing (NGS) and liquid biopsy techniques are transforming CRC diagnostics.
Purpose of the Study:
- To critically review the current landscape of CRC biomarkers.
- To explore promising future biomarkers for CRC screening, diagnosis, and prognosis.
- To highlight the impact of advanced technologies like NGS and AI on CRC biomarker discovery.
Main Methods:
- Literature review of current and emerging CRC biomarkers.
- Analysis of advancements in screening techniques like multi-target stool DNA (mt-sDNA) and Cologuard Plus.
- Exploration of novel biomarkers including Galectins, septins, and gut microbiome profiles (e.g., Fusobacterium nucleatum).
Main Results:
- Multi-target stool DNA (mt-sDNA) and Cologuard Plus are prominent screening tools.
- Galectins, septins, and Fusobacterium nucleatum show potential for early CRC detection.
- Circulating tumor cells and circulating DNA analysis via NGS are effective diagnostic and prognostic tools.
Conclusions:
- The field of CRC biomarkers is dynamic, with significant advancements in screening and diagnostics.
- Emerging biomarkers and technologies like AI hold great promise for improving CRC patient outcomes.
- Continued research into novel biomarkers is crucial for enhancing early detection and personalized treatment.
Related Concept Videos
01:30Serum Laboratory Studies, Stool Test, Breath Test
316
Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...
316
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K